XML 67 R52.htm IDEA: XBRL DOCUMENT v3.20.4
Revenue - Revenue Recognition (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Jun. 30, 2013
Disaggregation of Revenue [Line Items]        
Contract with customer, liability $ 57.1 $ 34.9    
Percentage of net sales 100.00% 100.00% 100.00%  
Americas | Revenue Benchmark | Geographic Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 48.00% 48.00% 48.00%  
Europe, Middle East, Africa | Revenue Benchmark | Geographic Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 43.00% 44.00% 44.00%  
Asia Pacific | Revenue Benchmark | Geographic Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 9.00% 8.00% 8.00%  
SmartDose        
Disaggregation of Revenue [Line Items]        
Contract with customer, liability $ 4.7      
Deferred income, current 0.9      
Deferred income, noncurrent $ 3.8      
High-Value Product Components | Revenue Benchmark | Product Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 46.00% 42.00% 41.00%  
High-Value Product Delivery Devices | Revenue Benchmark | Product Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 5.00% 5.00% 3.00%  
Standard Packaging | Revenue Benchmark | Product Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 26.00% 29.00% 32.00%  
Contract-Manufactured Products | Revenue Benchmark | Product Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 23.00% 24.00% 24.00%  
Biologics | Revenue Benchmark | Customer Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 31.00% 25.00% 21.00%  
Generics | Revenue Benchmark | Customer Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 20.00% 20.00% 21.00%  
Pharma | Revenue Benchmark | Customer Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 26.00% 31.00% 34.00%  
Contract-Manufactured Products | Revenue Benchmark | Customer Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 23.00% 24.00% 24.00%  
SmartDose        
Disaggregation of Revenue [Line Items]        
Contract with customer, liability       $ 20.0